Compass Pathways Finishes Its FDA Application for Psilocybin

Compass psilocybin FDA application: a rainbow psychedelic eye with the shape of the United States in the pupil

Quick take: The Compass psilocybin FDA application is complete, according to the company, and approval would be a first.

On November 9, Compass Pathways said it finished its New Drug Application for COMP360, according to its press release. It is a synthetic psilocybin for treatment-resistant depression. The company says the filing rests on two Phase 3 trials and one Phase 2b study. Together they involved more than 1,000 participants, and the company says each met its primary endpoint.

Now, the timing. The company says it has rolling review and a National Priority Voucher. It calls launch on track for the first half of 2027, subject to FDA approval.

What could slow the Compass psilocybin FDA application

Still, psilocybin is Schedule I. In other words, the DEA and states would have to reschedule it after any approval. The company says that may not happen on time, or at all. Also, it says the faster review may not materialize.

In fact, full trial data may not match the early results. Funding, insurance coverage and doctor adoption are open questions too. As a result, nobody can promise a date.

For context, the company says COMP360 also holds FDA Breakthrough Therapy designation. It cites about 4 million Americans with treatment-resistant depression, and says fewer than 5 percent are on a treatment indicated for it. Those are the company’s own figures. Chief executive Kabir Nath said the company is focused on delivering COMP360 as quickly as possible, subject to FDA approval.

We are cheering carefully. A real FDA decision on psilocybin would be huge for patients. Meanwhile, we will keep reading the fine print.

Why it matters to stoners: A federal approval would drag psilocybin into the mainstream. That helps everyone who wants saner drug laws.

Also, see our post on New Mexico’s psilocybin rules.



Leave a Reply